1. Long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloid polyneuropathy with or without cardiomyopathy: post hoc analysis of NEURO-TTR open-label extension. (14th October 2021) Authors: Whelan, C; Coelho, T; Conceicao, I; Brannagan Iii, T H; Wang, A K; Polydefkis, M J; Dyck, P J; Berk, J L; Obici, L; Kristen, A; Narayana, A; Olugemo, K; Aquino, P; Benson, M D; Gertz, M Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P.024 Long-term use of patisiran in patients with hereditary transthyretin amyloidosis (hATTR): 12 month efficacy & safety data from a global open label extension (OLE) study. (5th June 2019) Authors: Gonzalez-Duarte, A; Coelho, T; Adams, D; Yang, C; Polydefkis, M; Kristen, A; Tournev, I; Schmidt, H; Berk, J; Lin, K; Gandhi, PJ; Sweetser, M; White, M; Gollob, J; Suhr, OB Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P.024 Long-term use of patisiran in patients with hereditary transthyretin amyloidosis (hATTR): 12 month efficacy & safety data from a global open label extension (OLE) study. (June 2019) Authors: Gonzalez-Duarte, A; Coelho, T; Adams, D; Yang, C; Polydefkis, M; Kristen, A; Tournev, I; Schmidt, H; Berk, J; Lin, K; Gandhi, PJ; Sweetser, M; White, M; Gollob, J; Suhr, OB Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P.025 APOLLO, a phase 3 study of patisiran for the treatment of hereditary transthyretin amyloidosis (hATTR): 18-month safety and efficacy in subgroup with cardiac involvement. (5th June 2019) Authors: Vest, J; Solomon, S; Adams, D; Gonzalez-Duarte, A; O'Riordan, W; Yang, C; Coelho, T; Berk, J; Lin, K; Dyck, P; Gandhi, PJ; Sweetser, M; Suhr, OB; Kristen, A Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P.025 APOLLO, a phase 3 study of patisiran for the treatment of hereditary transthyretin amyloidosis (hATTR): 18-month safety and efficacy in subgroup with cardiac involvement. (June 2019) Authors: Vest, J; Solomon, S; Adams, D; Gonzalez-Duarte, A; O'Riordan, W; Yang, C; Coelho, T; Berk, J; Lin, K; Dyck, P; Gandhi, PJ; Sweetser, M; Suhr, OB; Kristen, A Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗